Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Adolescents with Obesity or Overweight
NCT06075667Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2023
- Primary completion
- Jun 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Percent Change from Baseline in Body Mass Index (BMI) at 72 weeks. Started Oct 2023; status: active, not recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06075667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075667.